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Background: Urotensin II (U-II) is highly expressed in the human lung and has been impli-
cated in regulating respiratory physiology in preclinical studies. Our objective was to test
antagonism of the urotensin (UT) receptor by GSK1440115, a novel, competitive, and selec-
tive inhibitor of the UT receptor, as a therapeutic strategy for the treatment of asthma.
Methods: Safety, tolerability, and pharmacokinetics (PK) of single doses of GSK1440115
(1–750 mg) were assessed in a Phase I, placebo controlled study in 70 healthy subjects.
In a Phase Ib study, 12 asthmatic patients were randomized into a two-period, single-blind
crossover study and treated with single doses of 750 mg GSK1440115 or placebo and given
a methacholine challenge.
Results:Administration of GSK1440115 was safe and well-tolerated in healthy subjects and
asthmatic patients. In both studies, there was a high degree of variability in the observed
PK following oral dosing with GSK1440115 at all doses. There was a marked food effect in
healthy subjects at the 50 mg dose. In the presence of food at the 750 mg dose, the time to
maximal concentration was between 2 and 6 h and the terminal half-life was short at approx-
imately 2 h. All asthmatic patients maintained greater than the predicted concentration
levels necessary to achieve predicted 96% receptor occupancy for≥3 h (between 4 and 7 h
post-dose). There were no apparent trends or relationships between the systemic plasma
exposure of GSK1440115 and pharmacodynamic endpoints, PC20 after methacholine chal-
lenge and FEV1, in asthmatics.
Conclusion: While GSK1440115 was safe and well-tolerated, it did not induce bronchodi-
lation in asthmatics, or protect against methacholine-induced bronchospasm, suggesting
that acute UT antagonism is not likely to provide benefit as an acute bronchodilator in this
patient population.
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INTRODUCTION
Asthma is characterized by blockage, narrowing, or constriction
of airways resulting in breathing difficulties with symptoms such
as coughing, wheezing, shortness of breath, or rapid breathing,
and chest tightness. It is a chronic disease affecting over 20 mil-
lion Americans and is either allergic (non-intrinsic triggered by
inhaled allergens) or non-allergic (triggered by intrinsic factors).
Despite available therapies, there is still an unmet medical need for
a safe, orally administered bronchodilator, particularly since long-
acting β agonists are undergoing increased scrutiny for potential
deleterious effects in this population (Sears, 2011).
Human urotensin II (hU-II) is a cyclic undecapeptide whose
actions are mediated by a specific cell surface G-protein-coupled
receptor, the urotensin II (U-II) receptor, UT (Ames et al., 1999;
Alexander et al., 2009). U-II was originally described as a potent
vasoconstrictor (Douglas et al., 2000). Since then, there has been
increasing evidence for U-II’s role in regulating respiratory physi-
ology. It is highly expressed in the lung (Zhang et al., 2002; Qi et al.,
2004), which is a major source of U-II in humans (Russell et al.,
2003). Similarly, U-II receptor expression has been localized to rat
airway smooth muscle cells where it functions as a growth fac-
tor (Chen et al., 2004; Zhang et al., 2012). Furthermore, U-II can
mediate smooth muscle contraction in isolated respiratory tract
and pulmonary arteries in primates (Douglas et al., 2000; Hay
et al., 2000; MacLean et al., 2000). Most recently, U-II has been
implicated in the remodeling of airways in asthmatic rats (Liang
et al., 2010). Finally, potent U-II receptor antagonists can block
U-II-induced contraction of isolated cat trachea muscle (Behm
et al., 2005).
GSK1440115 is a potent (Ki of 2.3 and 4.6 nM for recombinant
and native human UT receptors, respectively), competitive and
selective inhibitor of UT which mediates hU-II-induced systemic
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pressor response in anesthetized cats (Behm et al., 2010). Given the
evidence for a role for U-II in the lung,we tested whether UT antag-
onism, as mediated through GSK1440115, would be an effective
therapeutic strategy for the treatment of asthma. In this report, we
present the results of the first two clinical studies conducted with
GSK1440115. The first trial was a Phase I first-time-in-human
(FTiH) study to evaluate the safety, tolerability, and pharmaco-
kinetics (PK) of rising single doses of GSK1440115 in healthy
volunteers. The results of the FTiH study were used to design the
subsequent Phase Ib proof-of-mechanism study that evaluated the
activity of GSK1440115 in asthmatic subjects.
MATERIALS AND METHODS
STUDY DESIGN AND PARTICIPANTS
Phase I trial – first-time-in-human (healthy volunteers)
The FTiH trial was a randomized, single-blind (subjects and
investigator), placebo controlled, dose escalation study in healthy
volunteers (ClinTrials.gov identifier: NCT01202214). The spon-
sor was unblinded to study treatment. At least eight subjects were
enrolled in each of the nine cohorts, such that at least six subjects
randomly received the same dose of GSK1440115 and at least two
subjects received placebo. The study was composed of three peri-
ods for all subjects (screening, treatment, and follow-up). Safety,
PK and pharmacodynamics were assessed throughout the study.
Eligible subjects included healthy adult males and females
(of non-child-bearing potential) 18–65 years of age, inclusive.
Subjects had AST, ALT, alkaline phosphatase, and bilirubin
≤1.5×ULN (isolated bilirubin >1.5×ULN was acceptable if
bilirubin was fractionated and direct bilirubin was <35%) and
QTcB or QTcF<450 ms; or QTc<480 ms in subjects with Bundle
Branch Block (ClinTrials.gov identifier: NCT01424280).
The initial oral dose of GSK1440115 in the FTiH study was
calculated using multiple independent approaches including the
United States Food and Drug Administration (FDA) Guidance,
prediction of intrinsic human clearance using in vitro data from
human microsomes (with and without unbound fraction) (FDA
Guidance, 2005), and allometric and multiple species scaling based
on intravenous PK data from preclinical species. The human
starting doses were calculated using the lowest no adverse event
level (NOAEL) dose/exposure in the 28-days repeat dose toxi-
cology studies, and then applied a safety factor of 10-fold, or a
more conservative safety factor of 100-fold. The lowest NOAEL
exposure was the 1000 mg/kg dose in male rats with an area
under the concentration curve (AUC) of 25.6µg h/ml and a max-
imum observed concentration (Cmax) of 10.1µg/ml. The NOAEL
exposure in female rats and male/female dogs were higher, so
the male rat NOAEL exposure was considered the most con-
servative upper limit of the safety window, and was the lim-
iting exposure for this study. All starting dose considerations
indicated that a 1 mg dose would be a safe starting dose for
this study in healthy human volunteers with a wide anticipated
safety margin to the NOAEL in 28 days toxicology studies. Single
oral doses of GSK1440115 from 1 to 750 mg were evaluated in
humans.
Preliminary safety and PK data from each cohort were reviewed
prior to dose escalation and were used to determine the dose
administered in the subsequent cohort. The first five cohorts of
subjects were dosed in a fasted state according to the original pro-
tocol. Evaluation of the PK data from these early cohorts did not
show dose proportional increases in systemic exposure which was
thought to be due to the limits of drug dissolution or solubil-
ity. Since in vitro data with simulated gastric fluids suggested that
solubility in a fed environment would be enhanced, the protocol
was amended such that all subsequent dosing cohorts received the
study medication in the presence of food (high fat meal).
Phase Ib trial – proof-of-mechanism in asthmatic subjects
The second trial conducted was a two-period, single-blind (sub-
jects and investigator only), randomized crossover study in a
single cohort of asthmatics given single 750 mg oral doses of
GSK1440115 and placebo as shown in Figure 1 (ClinTrials.gov
identifier: NCT01424280). The sponsor was unblinded to study
treatment. The 750 mg dose of GSK1440115 was chosen based on
its observed safety and PK profiles in the FTiH study and PK/PD
modeling which predicted>96% receptor occupancy (RO) would
likely be maintained for several hours following dosing. Subjects
were randomized to participate in two treatment periods in which
a single oral dose of either GSK1440115 or placebo was admin-
istered. Each treatment period required two overnight stays at a
clinical unit. The treatment periods occurred 5–8 days apart.
Eligible subjects included males and females (non-child-
bearing potential) between 18 and 65 years of age with a docu-
mented history of bronchial asthma within the British Thoracic
Society guideline step 1–3, diagnosed at least 3 months prior to
the screening visit, but otherwise healthy. Eligibility also included
the following: best forced expiratory volume in 1 s (FEV1) of
>70% predicted normal value; hypersensitivity to methacholine
such that a baseline provocative concentration of methacholine
causing a 20% fall in FEV1 (PC20) was ≤4 mg/ml; increase in
PC20 of at least two dilutions compared to baseline in the pres-
ence of inhaled β-agonist in response to a methacholine challenge;
average QTcF <450 ms; or QTc <480 ms in subjects with Bundle
Branch Block; AST and ALT<2×ULN; alkaline phosphatase and
bilirubin ≤1.5×ULN.
Each of the two individual studies were conducted at sepa-
rate single sites in Australia according to the ethical principles of
“good clinical practice” (GCP) and the Declaration of Helsinki
after obtaining a written informed consent from each subject.
The protocol and amendments were all approved by the local
institutional review board (IRB).
PHARMACOKINETIC ASSESSMENTS
In the Phase I, FTiH study, blood samples for PK analysis were col-
lected at predose (0), 0.5, 1, 2, 4, 8, 12, 18, and 24 h post-dose and
a single trough sample on day 3 (approximately 8:00 AM). In the
Phase Ib proof-of-mechanism study, blood samples for PK analysis
were collected at predose (0), 2, 4, 6, 7, 12, and 24 h post-dose. Con-
centrations of GSK1440115 were determined in plasma samples
using a validated analytical method based on protein precipitation
followed by UHPLC/MS/MS analysis. The lower limit of quantifi-
cation (LLQ) for GSK1440115 was 1 ng/ml using a 50µL aliquot
of acidified human plasma with a higher limit of quantification
(HLQ) of 1000 ng/ml.
Frontiers in Pharmacology | Respiratory Pharmacology April 2013 | Volume 4 | Article 54 | 2
Portnoy et al. Antagonism of urotensin II receptor in asthma
FIGURE 1 | Study schematic. SABA, short acting β2 agonist.
PHARMACODYNAMIC ASSESSMENTS
In the Phase Ib study with asthmatic subjects, bronchodilation
effect via serial spirometry (FEV1) measurements and via atten-
uation of bronchoconstriction during a methacholine challenge
test were measured. Serial FEV1 measurements were performed at
predose and hourly up to 7 h following dosing. A methacholine
challenge test occurred at 7 h post-dose. The β-agonist, ventolin,
was administered (via spacer) and additional FEV1 assessments
were performed to document washout and responsiveness after
the methacholine challenge test.
STATISTICAL ANALYSES
The primary objectives of the FTiH study were to describe
the safety, tolerability, and PK in healthy volunteers follow-
ing single and repeat oral doses of GSK1440115. The primary
objective of the Phase Ib, proof-of-mechanism study was to
assess the effectiveness of a single oral dose of GSK1440115 to
protect against the bronchoconstrictive response induced dur-
ing a methacholine challenge test in asthmatic subjects who
were methacholine responders. The secondary objective for the
proof-of-mechanism study was to assess the bronchodilation of
GSK1440115 compared to placebo as determined by changes in
FEV1; to describe the safety and tolerability; and to characterize
the PK of GSK1440115.
For all safety data, summaries of actual value and changes from
baseline in the following parameters were generated: vital signs
[systolic blood pressure (SBP), diastolic blood pressure (DBP),
mean arterial blood pressure (MAP), and pulse rate], ECG val-
ues (ventricular rate, intervals of PR, QRS, QT, and QTc), clinical
chemistry and hematology values.
For PK data, listings of all derived parameters were generated.
For Cmax, tmax, AUC0–τ, AUC0–∞, t1/2, R, and λz, the following
summary statistics were calculated for each dose: n, arithmetic
mean, standard deviation, coefficient of variation, median, min-
imum, maximum, geometric mean, standard deviation of loga-
rithmically transformed data, and 95% confidence interval for the
geometric mean. For Cτ, regular descriptive statistics and 95%
confidence intervals about the arithmetic mean was calculated for
each dose. The PK-dose relationship was examined graphically by
plotting Cmax, AUC0–∞, and AUC0–τ as a function of the dose lev-
els administered. In practice, at least three dose levels were required
to assess dose proportionality.
For pharmacodynamic data, the methacholine PC20 for each
treatment was summarized categorically showing the counts and
percents for each dilution level. FEV1 was analyzed as a continu-
ous variable by treatment for each time point from 0 to 7 h (up to
the time of the methacholine challenge). An exploratory analysis
was performed to assess the relationship between GSK1440115
exposures and the primary and secondary pharmacodynamic
parameters.
RESULTS
DEMOGRAPHICS
In the FTiH study, 70 subjects were randomized to receive
a single dose of study medication (1–750 mg GSK1440115 or
placebo) across nine cohorts. All subjects were males and generally
well-matched demographically across all dose groups (Table 1).
A total of 12 subjects with asthma were randomized and treated
in the Phase Ib study with similar demographics in both treatment
groups (750 mg GSK1440115 or placebo; Table 1).
SAFETY
In the FTiH study, the frequency of reported AEs was low and
similar to placebo across all doses of GSK1440115 administered
(1–750 mg) in the fed or fasted states (Table 2). All reported AEs
were experienced by single subjects, except the AE of upper res-
piratory tract infection that was reported by two subjects in the
placebo group. The most frequently reported AEs across all reg-
imens, including placebo, were upper respiratory tract infection,
headache, and orthostatic hypotension. There were no deaths or
serious AEs during this study. There were no clinically significant
findings in clinical laboratory, or ECGs in this study. There were
no dose-related trends in changes in SBP, DBP, MAP, and heart
rate (HR), or peak expiratory flow.
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Overall, administration of GSK1440115 at doses up to 750 mg
was safe and well-tolerated in asthmatic subjects. A summary of
AEs reported in the Phase Ib study is provided in Table 3. In these
subjects, there were more AEs reported after administration of
GSK1440115 relative to placebo. AEs that were considered drug-
related included primarily headache and nausea followed by oral
herpes and decreased hemoglobin. A majority of AEs were mild in
intensity. There were no deaths or serious AEs during this study.
There were no clinically significant findings in clinical laboratory,
vital signs or ECGs in this study. There were no dose-related trends
in changes in SBP, DBP, MAP, HR, or peak expiratory flow.
PHARMACOKINETICS
In the FTiH study, there was a high degree of variability in the
PK data that did not allow for adequate overall assessment of the
PK profile for GSK1440155 in healthy volunteers. Exposures of
GSK1440115 were more than dose proportional in both the fed
and fasted states. A marked food effect was observed in the PK of
GSK1440115. At the 750 mg dose, the mean Cmax was 6833 ng/ml,
Table 1 | Summary of demographics in phase I and Ib trials – total
population.
Parameter Phase I (FTiH) study in
healthy subjects (N =70)
Phase Ib study in
asthmatic subjects (N =12)
Age (year)
Mean 26.7 28.3
Min, Max 19, 63 19, 38
Sex – n (%)
Male 70 (100.0) 10 (83.3)
Female 0 (0.0) 2 (16.7)
Race – n (%)
White 64 (91.4) 11 (91.7)
Asian 6 (8.6) 1 (8.3)
Other 0 (0.0) 0
Height (cm)
Mean 179.1 178.7
Min, Max 166, 198 167, 192
the mean AUC(0–∞) was 35432 ng h/ml and the median tmax was
8 h. All subjects dosed at the 750 mg dose level achieved concen-
trations of GSK1440115 that were predicted to be associated with
>96% RO based on previous preclinical RO modeling (96% RO
was predicted at concentration of 575 ng/ml). All subjects main-
tained concentration levels above this threshold for at least 3 h
(between 4 and 7 h post-dose).
Pharmacokinetics data from the Phase Ib study are summarized
in Table 4 which was consistent with the healthy volunteer data
at the same 750 mg dose. GSK1440115 was detectable in all asth-
matic subjects at 2 h (first post-dose timepoint).Tmax was reached
between 2 and 6 h (median: 6 h) and all subjects had measurable
concentrations at 24 h post-dose (last PK time point).
PHARMACODYNAMICS IN ASTHMATICS
For the analysis of methacholine PC20, a clinically relevant effect
was defined as a mean single double dilution increase beyond
placebo; however, this effect was not observed in this study. As
shown in Figure 2, the majority of subjects did not have metha-
choline dose doubling compared to placebo. The probability that
the true population mean attained this clinically relevant effect was
0.0237, falling short of ≥0.55 that would be considered effective.
The secondary endpoint, FEV1, was analyzed as a continuous
variable by treatment for each time point from 0 to 7 h. A clini-
cally relevant effect was defined as a mean increase in predicted
FEV1 of 0.1 L. In this study, for both GSK1440115 and placebo, the
mean FEV1 values (solid lines) over time were below what would
be considered a clinically relevant (Figure 3). The probability the
true population mean attainted this clinically relevant effect was
0.0014. The 95% credible interval (hashed lines) for the differ-
ence in FEV1 beyond placebo was (−0.1276, 0.0508) indicating
no significant difference.
There were no apparent trends or relationships between the
systemic plasma exposure of GSK1440115 and either pharmaco-
dynamic endpoint, PC20, and FEV1.
DISCUSSION
Although no information exists on the role of U-II in the control of
respiratory physiology in humans, available data in the literature is
Table 2 | Summary of all adverse events (related and unrelated) in ≥2 subjects – phase I study in healthy volunteers.
Adverse event Number of subjects reporting adverse events
Fast/Fed GSK1440115 fasted GSK1440115 fed
Placebo 1mg 5mg 15mg 50mg 100mg 50mg 150mg 450mg 750mg Total
N =18 N =6 N =6 N =6 N =4 N =6 N =6 N =6 N =6 N =6 N =70
Subjects with any AE 6 (33%) 2 (33%) 3 (50%) 2 (33%) 1 (25%) 3 (50%) 1 (17%) 2 (33%) 2 (33%) 2 (33%) 24 (34%)
Upper respiratory tract infection 2 (11%) 1 (17%) 0 1 (17%) 0 1 (17%) 0 0 0 0 5 (7%)
Headache 1 (6%) 0 0 1(17%) 0 1 (17%) 0 1 (17%) 0 0 4 (6%)
Orthostatic hypotension 1 (6%) 0 0 0 1 (25%) 0 0 0 0 1 (17%) 3 (4%)
Dizziness 1 (6%) 0 0 0 0 0 0 0 1 (17%) 0 2 (3%)
Tremor 1 (6%) 0 1 (17%) 0 0 0 0 0 0 0 2 (3%)
Presyncope 0 0 1 (17%) 0 0 0 1 (17%) 0 0 0 2 (3%)
Bolded values represent AEs considered drug-related by the investigator.
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highly suggestive of a potential role of U-II and its receptor system
in bronchial tone in several preclinical species providing a ratio-
nale for its evaluation in humans (Hay et al., 2000; De Garavilla
et al., 2001; Behm et al., 2005). The purpose of these studies was to
investigate the safety, tolerability, and the potential role of a novel
UT antagonist, GSK1440115, as a bronchodilator in humans.
Both the Phase I study in healthy volunteers and the Phase Ib
proof-of-mechanism study in asthmatics showed that administra-
tion of GSK1440115 from 1 to 750 mg was safe and well-tolerated.
In both studies, there was high degree of variability in the observed
PK following oral dosing with GSK1440115 at all doses. There was
a marked food effect in healthy volunteers at the 50 mg dose. In
the fasted state,AUC exposures were approximately two-fold lower
than when administered with a high fat meal. In the presence of
food with the 750 mg dose in the Phase 1b study, the time to
maximal concentration was between 2 and 6 h and the terminal
half-life was short at approximately 2 h. All subjects maintained
Table 3 | Summary of adverse events – phase Ib study in asthmatic
subjects.
Adverse event GSK1440115
(N =12)
n (%)
Placebo
(N =12)
n (%)
All treatments
(N =12)
n (%)
Subjects with any AE 9 (75.0) 6 (50.0) 10 (83.3)
Nausea 5 (41.7) 1 (8.3) 5 (41.7)
Vomiting 1 (8.3) 0 (0.0) 1 (8.3)
Gastroenteritis viral 1 (8.3) 0 (0.0) 1 (8.3)
Oral herpes 1 (8.3) 0 (0.0) 1 (8.3)
Viral upper respiratory tract
infection
0 (0.0) 1 (8.3) 1 (8.3)
Contusion 0 (0.0) 1 (8.3) 1 (8.3)
Laceration 0 (0.0) 1 (8.3) 1 (8.3)
Hemoglobin decreased 1 (8.3) 0 (0.0) 1 (8.3)
Liver function test abnormal 1 (8.3) 0 (0.0) 1 (8.3)
Headache 5 (41.7) 1 (8.3) 6 (50.0)
Presyncope 1 (8.3) 0 (0.0) 1 (8.3)
Rhinorrhea 0 (0.0) 1 (8.3) 1 (8.3)
Wheezing 0 (0.0) 1 (8.3) 1 (8.3)
Dermatitis contact 0 (0.0) 1 (8.3) 1 (8.3)
Eczema 0 (0.0) 1 (8.3) 1 (8.3)
greater than the predicted concentration levels necessary to achieve
96% RO for at least 3 h (between 4 and 7 h post-dose). There were
no apparent trends or relationships between the systemic plasma
exposure of GSK1440115 and either pharmacodynamic endpoint,
PC20 and FEV1.
Contrary to data observed in preclinical models, the results of
the proof-of-mechanism study with GSK1440115 indicated that
a U-II receptor antagonist may not be an effective agent as an
acute acting oral bronchodilator for treatment of asthma. In asth-
matic subjects, 750 mg dose of GSK1440115 lacked any measurable
activity as an oral bronchodilator (FEV1) and demonstrated an
inability to protect against methacholine-induced bronchocon-
striction. Volunteers selected for this trial were required to first
demonstrate a minimum baseline PC20 in response to metha-
choline (the concentration of methacholine needed to reduce
FEV1 by 20%) and were required to demonstrate a minimum
improvement in PC20 following an inhaled short acting β-agonist
(SABA; ventolin) of at least a two double dilution improvement.
Based on the PK profile of the FTiH study in healthy volunteers, in
which Tmax was achieved between 4 and 7 h, the methacholine
challenge was conducted 7 h after drug administration, a time
at which the subjects were expected to have achieved 96% RO.
GSK1440115, however, failed to demonstrate any change in PC20
in response to a methacholine challenge compared to placebo. The
decision rule for this study was based on a posterior probability
of a true effect being greater than only 1 double dilution (i.e.,
a “low hurdle”) and provided a 90% probability that the study
would correctly identify an effect if the true effect was in fact two
double dilutions (comparable to ventolin). However, based on the
PC20 data, the probability that GSK1440115 offers an effect size of
>1 double dilution beyond placebo in the methacholine challenge
model was only 2.37%. Volunteers also demonstrated appropriate
changes in FEV1 in response to SABA at screening, but no move-
ment in FEV1 on GSK1440115 was observed during the treatment
period compared to placebo. The probability that an effect size
of >0.1 L increase in FEV1 over placebo (considered a clinically
relevant effect) during the dosing period was 0.14%.
Based upon the available data from these studies it is apparent
that antagonism of UT receptor with a single dose of GSK1440115
does not result in bronchodilation. These results suggest that
endogenous hU-II does not play a direct role in regulating
bronchomotor tone, potentially a result of low UT expression in
Table 4 | Summary of pharmacokinetic data after administration of 750mg dose of GSK1140115 in asthmatic subjects.
Pharmacokinetics parameters n Mean (CV) Median Geometric mean (CV) Range (min, max)
Cmax (ng/mL) 12 8473 (55%) 7292 7267 (66%) (2409, 16605)
tlag (h) 12 0 0 n/e (0, 0)
tmax (h) 12 n/e 6.0 n/e (2,6)
AUC (0–t) (ng h/mL) 12 39340 (65%) 29539 32112 (76%) (12084, 88351)
AUC (0-∞) (ng h/mL) 12 39365 (65%) 29548 32137 (76%) (12099, 88421)
λz (1/h) 12 0.3598 (12%) 0.3564 0.3575 (12%) (0.287, 0.414)
t1/2 (h) 12 1.95 (12%) 1.95 n/e (1.68, 2.42)
n/e, not estimated; CV, coefficient of variation; SD, standard deviation.
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FIGURE 2 | Individual PC20 effects and methacholine dose doublings.
(A)The target effect in this study was defined as a mean single double
dilution increase (solid vertical line). As shown, the majority of subjects did
not have methacholine dose doubling compared to placebo. The probability
that the true population mean attained this clinically relevant effect was
0.0237, falling short of ≥0.55 that would be considered effective.
(B) Metahcholine concentrations presented by treatment. GSK,
GSK1440115; PBO, placebo.
human bronchiolar tissue (Maguire et al., 2000). Interestingly, it
is unknown whether or not UT expression is altered in asthmatic
patients. Although the precise reason for the lack of bronchodila-
tor activity in the present study is unidentified, it is unlikely that
it is a result of limited drug exposure. Indeed, all subjects dosed
with 750 mg GSK1440115 achieved concentrations that were pre-
dicted to be associated with >96% RO. This is in contrast to
palosuran which exhibits low hUT receptor affinity/activity in
intact cells and tissue membranes, offering a potential explanation
for the lack of clinical efficacy reported with palosuran in diabetic
nephropathy patients (Behm et al., 2008). Preclinical distribution
studies with GSK1440115 resulted in wide distribution into the
peripheral tissues, including lung, which suggests that access to
the UT receptor would not be the limiting factor.
FIGURE 3 | Mean FEV1 values over time. A clinically relevant effect was
defined as a mean increase in predicted FEV1 of 0.1 l. For both GSK1440115
and placebo the mean FEV1 values (solid lines) over time were below what
would be considered a clinically relevant. The probability the true population
mean attainted this clinically relevant effect was 0.0014. The 95% credible
interval (hashed lines) for the difference in FEV1 beyond placebo was
(−0.1276, 0.0508) indicating no significant difference.
Since the primary goal of this study was to investigate the
specific hypothesis of protection against acute bronchospasm
following a direct challenge through the use of an oral urotensin
antagonist, an alternative challenge modality, such as an aller-
gen associated with late phase inflammatory reactions, was not
investigated. Furthermore, a meaningful assessment of allergen
associated effects following single dose administration of this agent
was not anticipated.
It is important to note that only a single dose of GSK1440115
was tested in this study for a potential acute effect. Although no
acute bronchodilator effect was observed in the present study, U-II
has been shown to play a predominant role in airway remodel-
ing in asthmatic rats (Liang et al., 2010), suggesting that chronic
dosing with GSK1440115 might be useful for preventing or revers-
ing human airway remodeling associated with asthma or other
respiratory diseases. Additional studies are required to test this
hypothesis.
In summary, GSK1440115 does not induce bronchodilation in
asthmatic subjects, suggesting that acute UT antagonism will not
be of benefit in this patient population. Although GSK1440115
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elicited no bronchodilator effect, acute treatment with the com-
pound was safe and well-tolerated, supporting further use of
GSK1440115 as a clinical tool for investigating the role of the U-II
system in human disease.
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